Anupam Rasayan India Ltd Share Price – NSE  / BSE

Chemicals, Small Cap

Anupam Rasayan India (ARIL) has received credit ratings for bank facilities (Rs 1620 crore) and non-convertible debentures (Rs 160 crore) at CRISIL A+/ CRISIL A1. These ratings are placed on 'Rating Watch with Developing Implications'.

The ratings have been placed on watch following announcement by ARIL of acquisition of 43.3-48.2% equity stake in Bliss GVS Pharma, a pharmaceutical (pharma) formulations company based in India, which may be funded through debt, equity or internal accrual.

Anupam Rasayan India announced that the Board of Directors of the Company at its meeting held on 23 May 2026, inter alia, have recommended the final dividend of Rs 1.5 per equity Share (i.e. 15%) , subject to the approval of the shareholders.

Net profit of Anupam Rasayan India declined 4.31% to Rs 42.65 crore in the quarter ended March 2026 as against Rs 44.57 crore during the previous quarter ended March 2025. Sales rose 27.12% to Rs 635.78 crore in the quarter ended March 2026 as against Rs 500.16 crore during the previous quarter ended March 2025.

For the full year,net profit rose 82.24% to Rs 170.12 crore in the year ended March 2026 as against Rs 93.35 crore during the previous year ended March 2025. Sales rose 64.61% to Rs 2365.46 crore in the year ended March 2026 as against Rs 1436.97 crore during the previous year ended March 2025.

Powered by Capital Market - Live News

Anupam Rasayan India will hold a meeting of the Board of Directors of the Company on 23 May 2026.